BBIO stock sentiment todayBridgeBio Pharma, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
BBIO
BridgeBio Pharma, Inc.BridgeBio is transitioning from a R&D-heavy biotech to a commercial powerhouse following the FDA approval of Attruby (acoramidis).
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for BBIO. Not financial advice.
Price · last 12 months
Gossip
The market narrative is dominated by the recent FDA approval of Attruby for ATTR-CM, positioned as a best-in-class competitor to Pfizer’s Vyndaqel. Investors are focused on the rapid commercial launch and the potential for BBIO to be a prime M&A target for Big Pharma looking to bolster their cardiovascular portfolios.
- ·FDA approval of acoramidis (Attruby)
- ·M&A speculation surrounding cardiovascular-focused biotechs
- ·Positive Phase 3 data in achondroplasia (infigratinib)
- ·High short-interest coverage potential
Financial
While currently loss-making due to high R&D spend, the balance sheet was recently bolstered by a royalty deal with Blue Owl and Kyowa Kirin, providing a significant cash runway to fund the commercial launch. Revenue is expected to scale exponentially starting in 2025.
- ·Cash runway into 2026
- ·Projected peak sales for Attruby exceeding $2B
- ·Significant institutional ownership (>90%)
- ·Enterprise Value/Pipeline potential remains attractive relative to peers
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Commercial execution risk against Pfizer's established market share
- ·Potential dilution if additional capital is raised for global expansion
- ·Regulatory hurdles for earlier-stage pipeline assets
Peer temperature
How direct competitors stack up against BBIO right now.
- NEUTRALALNYAlnylam Pharmaceuticals
COLDER — While established, its RNAi platform faces higher manufacturing costs and stricter administration routes compared to BBIO’s oral small molecule.
See full analysis → - COLDPFEPfizer Inc.
COLDER — Facing massive patent cliffs and declining COVID-19 revenue, lacking the high-growth explosive potential of a mid-cap biotech like BBIO.
See full analysis → - HOTVRTXVertex Pharmaceuticals
HOTTER — Offers a more stable, diversified cash-flow profile and a dominant monopoly in CF, though with less immediate 'multi-bagger' upside than BBIO.
See full analysis →
- BBIO+13.9%
- ALNY-33.1%
- PFE+7.0%
- VRTX+6.9%
Analyst price target
Consensus average of 19 analysts · median 110.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.